engleski

Estrogen modulates IgG glycosylation in women

Immunoglobulin G (IgG) is an important immune response mediator and specific IgG glycoforms exert different immune response effects. Glycosylation of IgG differs in patients suffering from various diseases (such as tumors and inflammatory and autoimmune diseases), but also in people with different physiological parameters, such as age and sex. Major differences in IgG glycosylation occur when females experience sex hormonal changes, like in pregnancy, late puberty and with entering the menopause. However, current knowledge on the associations of female sex hormones and IgG glycosylation is mostly based on epidemiological studies. Here we present an experimental study aiming to investigate the effect of estrogen on IgG glycosylation. Participants were healthy premenopausal women with normal menstrual cycle function that were deprived of estrogen with monthly injections of gonadotropin-releasing hormone agonist (GnRHAG) therapy for 5 months. During hormonal intervention therapy, one group was given estrogen supplementation in a weekly transdermal estradiol (E2) patches and the other group received placebo. The study terminated with the recovery of normal menstrual cycle function throughout the period of 4 months. Each participant was tested 3 times during the study: in the last menstrual cycle before starting hormonal intervention, after hormonal intervention and in the menstrual cycle after recovery of normal menstrual cycle function. Each time a volume of 5 ml of peripheral blood was drawn and serum was obtained. IgG was isolated from serum samples by affinity chromatography on a protein G monolithic plate and its N glycans were released by PNGase F, labeled with 2 aminobenzamide and analyzed by hydrophilic interaction ultra-performance liquid chromatography. Using this approach, we were able to monitor the effect of estrogen deficiency on IgG glycosylation.

estrogen, women, IgG glycosylation, sialylation, galactosylation

nije evidentirano